Their study revealed that the dynamic regulation of extrachromosomal mutant EGFR DNA contributes to the development of resistance to targeted therapy, emphasizing the need for new strategies to overcome these challenges in GBM treatment. The gene discussed is EGFR; the disease is glioblastoma.